Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech filings can read like a clinical protocol—hundreds of pages on Phase-3 endpoints, safety signals and cash burn. Galera Therapeutics’ documents add another layer with superoxide dismutase mimetics such as avasopasem and rucosopasem. If you’re searching for “Galera Therapeutics SEC filings explained simply” or want to pinpoint how its cash runway funds the ROMAN trial, Stock Titan’s AI turns dense language into plain-English highlights. For professionals “understanding Galera Therapeutics SEC documents with AI” is now a reality.
Our platform streams every form straight from EDGAR the moment it posts. Need “Galera Therapeutics quarterly earnings report 10-Q filing” to gauge R&D spend? One click shows AI-generated tables and peer comparisons. Tracking “Galera Therapeutics insider trading Form 4 transactions” is effortless—real-time alerts flag each executive stock move, so you never miss “Galera Therapeutics Form 4 insider transactions real-time.” Our dashboard groups “Galera Therapeutics executive stock transactions Form 4” by insider and date. We also map 8-K material events—trial readouts, FDA feedback, financing—to concise summaries, perfect for investors who Google “Galera Therapeutics 8-K material events explained.”
Dig deeper with filing-specific guides. The annual report section, labeled “Galera Therapeutics annual report 10-K simplified,” breaks down pipeline status, patent cliffs and milestone payments. The “Galera Therapeutics proxy statement executive compensation” tab decodes option grants and severance triggers. Need quick context before a call? Our AI produces an on-demand “Galera Therapeutics earnings report filing analysis.” Each insight links directly back to the source page, helping portfolio managers, analysts and clinicians understand the science, the finances and the strategic alternatives—all without getting lost in regulator jargon.
Galera Therapeutics, Inc. (GRTX) president and CEO J. Mel Sorensen, who is also a director, reported an open market sale of company stock. On 11/20/2025, he sold 70,000 shares of common stock at a weighted average price of $0.0201 per share, with individual trades executed between $0.02 and $0.0201. After this transaction, he beneficially owned 195,029 shares of Galera Therapeutics common stock in direct ownership.
GRTX has a Form 144 notice indicating that an affiliate plans to sell up to 70,000 shares of common stock through Raymond James & Associates on the OTC Markets, with an approximate sale date of 11/20/2025 and an aggregate market value of
Galera Therapeutics (OTCQB:GRTX) reported a smaller quarterly loss and a strategic reset. For the quarter ended September 30, 2025, net loss was $1.4 million versus $5.6 million a year ago as operating expenses fell sharply; research and development was $0.1 million and general and administrative was $1.3 million.
Cash and cash equivalents were $4.5 million, with total assets of $5.0 million and a stockholders’ deficit of $149.2 million. A royalty purchase liability of $151.0 million remained on the balance sheet at quarter‑end, and was subsequently assigned to Biossil alongside the sale of the company’s dismutase mimetic assets for $3.5 million in October 2025. Management states that existing cash plus the $3.5 million will fund limited operations for at least twelve months from issuance.
The business has shifted to a pan‑NOS inhibitor program for difficult breast cancers. An investigator‑sponsored Phase 1/2 study at Houston Methodist is funded by an NIH grant, and a second TNBC trial is being planned with the I‑SPY 2 consortium, subject to additional capital. In December 2024, Galera acquired Nova Pharmaceuticals and issued 119,318 Series B non‑voting convertible preferred shares (each convertible into 1,000 common shares if approved), and completed a $2.9 million private placement at $0.065 per share or pre‑funded warrant. Common shares outstanding were 75,462,390 as of November 12, 2025.
Galera Therapeutics (GRTX) reported that Blackstone executed a notice of assignment acknowledging Galera’s assignment of the Amended and Restated Purchase and Sale Agreement to Biossil Inc. and agreeing to look solely to Biossil for all obligations of the “Seller” under that agreement.
This step follows Galera’s Asset Purchase and Sale Agreement under which it sold all of its dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711), to Biossil, with Biossil assuming liabilities related to those assets. The notice of assignment was executed after the transaction and is filed as Exhibit 10.1.
Galera Therapeutics (GRTX) agreed to sell its avasopasem (GC4419), rucosopasem (GC4711), and other dismutase mimetic assets to Biossil Inc. under an Asset Purchase and Sale Agreement, as amended.
The purchase price includes an upfront payment of $3,500,000 and potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105,000,000 in aggregate. Biossil also agreed to assume all further rights and obligations of Galera under the Amended and Restated Purchase and Sale Agreement dated November 14, 2018, with Clarus IV Galera Royalty AIV, L.P., which is affiliated with Blackstone Life Sciences.
The agreement includes customary representations, warranties, and covenants, with certain confidentiality, indemnification, and payment provisions surviving closing. Galera plans to file the full agreement as an exhibit to its next Form 10-Q.
FAQ
What is the current stock price of Galera Therapeutics (GRTX)?
What is the market cap of Galera Therapeutics (GRTX)?
